Evidence map›Paper›PMID 38038373›Full record

ArticleThe international journal of neuropsychopharmacology2024

MiR-182-5p: A Novel Biomarker in the Treatment of Depression in CSDS-Induced Mice.

Ya-Bin Zheng, Xiao-Ming Sheng, Xiang Jin, Wei Guan

Open access · goldAbstract read
In one paragraph

Article in The international journal of neuropsychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 9 citations in OpenAlex.

  1. Association between miR-182 rs76481776 Polymorphism and Antidepressant Treatment Response in Patients with Depression.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026
    Article
  2. Article
  3. Review
  4. Neurobiology of stress · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ya-Bin ZhengDepartment of Neurology, The second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Xiao-Ming ShengDepartment of Trauma Center, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Xiang JinDepartment of Pharmacy, The Second People's Hospital of Nantong, Nantong, Jiangsu, China.
Wei GuanDepartment of Pharmacology, Pharmacy College, Nantong University, Nantong, Jiangsu, China.
Nantong University · CNNanjing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDepression is a neuropsychiatric disease with a high disability rate and mainly caused by the chronic stress or genetic factors. There is increasing evidence that microRNAs (miRNAs) play a critical role in the pathogenesis of depression. However, the underlying molecular mechanism for the pathophysiology of depression of miRNA remains entirely unclear so far.

methodsWe first established a chronic social defeat stress (CSDS) mice model of depression, and depression-like behaviors of mice were evaluated by a series of behavioral tests. Next, we detected several abundantly expressive miRNAs suggested in previous reports to be involved in depression and found miR-182-5p was selected as a candidate for analysis in the hippocampus. Then western blotting and immunofluorescence were used together to examine whether adeno-associated virus (AAV)-siR-182-5p treatment alleviated chronic stress-induced decrease in hippocampal Akt/GSK3β/cAMP-response element binding protein (CREB) signaling pathway and increase in neurogenesis impairment and neuroinflammation. Furthermore, CREB inhibitor was adopted to examine if blockade of Akt/GSK3β/CREB signaling pathway abolished the antidepressant actions of AAV-siR-182-5p in mice.

resultsKnockdown of miR-182-5p alleviated depression-like behaviors and impaired neurogenesis of CSDS-induced mice. Intriguingly, the usage of agomiR-182-5p produced significant increases in immobility times and aggravated neuronal neurogenesis damage of mice. More importantly, it suggested that 666-15 blocked the reversal effects of AAV-siR-182-5p on the CSDS-induced depressive-like behaviors in behavioral testing and neuronal neurogenesis within hippocampus of mice.

conclusionsThese findings indicated that hippocampal miR-182-5p/Akt/GSK3β/CREB signaling pathway participated in the pathogenesis of depression, and it might give more opportunities for new drug developments based on the miRNA target in the clinic.

Indexed as

Behavior, AnimalMicroRNAsAnimalsCyclic AMP Response Element-Binding ProteinGlycogen Synthase Kinase 3 betaHippocampusMiceProto-Oncogene Proteins c-aktSocial DefeatStress, PsychologicalCyclic AMP Response Element-Binding ProteinGlycogen Synthase Kinase 3 betaMicroRNAsProto-Oncogene Proteins c-aktchronic social defeat stressCREBdepressionMechanismMiR-182-5pneuronal neurogenesis

Identifiers

PMID38038373
PMCPMC10799762
OpenAlexW4389218285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.